title: Patterns of treatment with PDE5 inhibitors in the clinical practice in Italy: longitudinal data from the Erectile Dysfunction Observational Study.
abstract: The Erectile Dysfunction Observational Study (EDOS) is a 6-months observational prospective multicentric study enrolling men with erectile dysfunction (ED) who asked, to be started on a treatment or to change a previous treatment. Aims of the study were to analyse the pattern of treatment and compare the efficacy of treatments used. Patients were enrolled during a normal hospital visit and were prescribed a treatment for ED. They were asked at baseline and after 3 and 6 months, to answer a set of questions from the International Index of Erectile Function, Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) and Short Form of the Psychological and Interpersonal Relationships Scale questionnaires (SF-PAIRS). Clinicians were free to prescribe any therapy for ED available in the market, and to change therapy at any time during the study. Out of 1 338 patients, available for analysis at 6 months, 624 (47%) changed their treatment during the study and 714 (53%) continued with the drug prescribed at baseline. Patients assuming tadalafil had a significantly higher probability of maintaining the same treatment compared to sildenafil or vardenafil. There was no clinically significant difference in terms of efficacy, patient satisfaction, self-confidence and spontaneity between the different inhibitors of PDE5. The 'time concerns' domain score of SF-PAIRS, was statistically better in patients assuming tadalafil. In conclusion sildenafil, vardenafil and tadalafil show similar efficacy in the clinical practice. However, patients receiving tadalafil display a lower risk to discontinue or change the treatment.
authors.affiliation: Clinica Urologica - Università Federico II, Napoli 80100, Italy. ferdinando-fusco@libero.it
authors.forename: Ferdinando
authors.initials: F
authors.lastname: Fusco
authors.forename: Riccardo
authors.initials: R
authors.lastname: Sicuteri
authors.forename: Andrea
authors.initials: A
authors.lastname: Rossi
authors.forename: Stathis
authors.initials: S
authors.lastname: Kontodimas
authors.forename: Jose Maria
authors.initials: JM
authors.lastname: Haro
authors.forename: Ciro
authors.initials: C
authors.lastname: Imbimbo
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Mirone
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002243:Carbolines / Q000627:therapeutic use*; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data; D011687:Purines / Q000627:therapeutic use; D000068677:Sildenafil Citrate; D013450:Sulfones / Q000627:therapeutic use*; D000068581:Tadalafil; D016896:Treatment Outcome; D014227:Triazines / Q000627:therapeutic use; D000069058:Vardenafil Dihydrochloride
chemical_list: D002243:Carbolines; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D000068581:Tadalafil; D000068677:Sildenafil Citrate
references.citation: Am J Psychiatry. 1999 Jan;156(1):5-10
references.pmid: 9892291
references.citation: Diabetologia. 2004 Nov;47(11):1914-23
references.pmid: 15599697
references.citation: Urology. 2001 May;57(5):960-5
references.pmid: 11337303
references.citation: Asian J Androl. 2006 Nov;8(6):675-84
references.pmid: 16892168
references.citation: Spinal Cord. 2004 Nov;42(11):643-8
references.pmid: 15289800
references.citation: J Urol. 1999 Nov;162(5):1614-7
references.pmid: 10524880
references.citation: Int J Impot Res. 2004 Jun;16(3):207-13
references.pmid: 15164088
references.citation: Int J Impot Res. 1997 Sep;9(3):141-8
references.pmid: 9315491
references.citation: BJU Int. 2005 Dec;96(9):1323-32
references.pmid: 16287454
references.citation: Clin Ther. 2003 Nov;25(11):2724-37
references.pmid: 14693300
references.citation: Eur Urol. 2004 Apr;45(4):499-507; discussion 507-9
references.pmid: 15041116
references.citation: Int J Clin Pract. 2004 Mar;58(3):230-9
references.pmid: 15117088
references.citation: Clin Ther. 2003 Nov;25(11):2709-23
references.pmid: 14693299
references.citation: JAMA. 1999 Feb 3;281(5):421-6
references.pmid: 9952201
references.citation: BJU Int. 2006 Sep;98(3):623-9
references.pmid: 16925764
references.citation: Eur Urol. 2006 Jan;49(1):30-7
references.pmid: 16263207
references.citation: J Urol. 2004 Sep;172(3):1036-41
references.pmid: 15311032
references.citation: BJU Int. 2004 Jun;93(9):1276-81
references.pmid: 15180622
references.citation: Eur Urol. 2007 Feb;51(2):541-50; discussion 550
references.pmid: 17084518
references.citation: Am J Cardiol. 2003 Nov 6;92(9A):47M-57M
references.pmid: 14609623
references.citation: Arch Ital Urol Androl. 2007 Mar;79(1):1-6
references.pmid: 17484395
references.citation: J Sex Med. 2004 Sep;1(2):150-60
references.pmid: 16422969